Adeshwar Meditex

Why is Adeshwar Meditex Ltd falling/rising?

As of 01-Sep, the stock price of Adeshwar Meditex Ltd is at 16.95, unchanged from the previous session. Despite a year-to-date increase of 5.94%, the stock has underperformed its sector today and shows declining investor participation, indicating potential challenges for future price growth.

As of 01-Sep, the stock price of Adeshwar Meditex Ltd is currently at 16.95, with no change from the previous trading session. The stock has shown a mixed performance over various periods, with a year-to-date increase of 5.94%, while the benchmark Sensex has decreased by 9.71% in the same timeframe. However, despite this positive year-to-date performance, the stock has underperformed its sector today by 3.72%.<BR><BR>In terms of trading activity, the stock has exhibited erratic trading patterns, having not traded on 4 out of the last 20 days. Additionally, there has been a significant decline in investor participation, with a delivery volume of 0 on July 30, indicating a 100% drop compared to the 5-day average delivery volume. This lack of trading activity and falling investor participation suggests a lack of confidence among investors, which could be contributing to the stock's stagnation at its current price.<BR><BR>Furthermore, while the stock is currently trading above its 5-day and 20-day moving averages, it remains below its 50-day, 100-day, and 200-day moving averages, indicating a potential bearish trend in the longer term. Overall, the combination of underperformance against the sector, erratic trading, and declining investor interest suggests that the stock is facing challenges that may hinder its price from rising.

Which are the latest news on Adeshwar Meditex?

Who are in the management team of Adeshwar Meditex?

The management team of Adeshwar Meditex includes Ashalata Raut and Krishnojirao Nagaraja Rao as Whole-time Directors, Sucheta Talati and Shailesh Vinayak Rajpure as Directors, and Shivani Shivshankar Tiwari as Company Secretary.

The management team of Adeshwar Meditex includes the following individuals:<BR><BR>1. **Ashalata Raut** - Whole-time Director<BR>2. **Krishnojirao Nagaraja Rao** - Whole-time Director<BR>3. **Sucheta Talati** - Director<BR>4. **Shivani Shivshankar Tiwari** - Company Secretary<BR>5. **Shailesh Vinayak Rajpure** - Director<BR><BR>If you need more details about their roles or the company, feel free to ask!

What does Adeshwar Meditex do?

Adeshwar Meditex Ltd is a manufacturer and exporter of sterile surgical wound dressings and medical disposables, operating in the Healthcare Services industry. The company was incorporated in 2007 and has a market cap of INR 25 Cr, with key metrics including a P/E ratio of 19.00 and a debt-equity ratio of 0.16.

Overview: <BR>Adeshwar Meditex Ltd is a leading manufacturer and exporter of sterile surgical wound dressings and medical disposables, operating in the Healthcare Services industry within the Micro Cap market.<BR><BR>History: <BR>Adeshwar Meditex Limited was incorporated as a private limited company on April 02, 2007, and was later converted into a public limited company on March 09, 2021. Revenue and profit data for the latest quarter are not available.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: N/A <BR>Market-cap value: INR 25 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 19.00 <BR>Industry P/E: N/A <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.16 <BR>Return on Equity: 3.29% <BR>Price-to-Book: 0.66<BR><BR>Contact Details: <BR>No Company Details Available <BR>Registrar Address: Not available.

Who are the peers of the Adeshwar Meditex?

Adeshwar Meditex's peers include GKB Ophthalmics, Chennai Meena, Tejnaksh Health, and others, with varying management risks and growth rates. Dhanvantri Jeev. leads in 1-year returns at 26.19%, while Adeshwar Meditex lacks available return data.

Peers: The peers of Adeshwar Meditex are GKB Ophthalmics, Chennai Meena, Tejnaksh Health., Samsrita Labs, Transgene Biotek, Vanta Bioscience, Family Care, Dhanvantri Jeev., and Galaxy Medicare.<BR><BR>Quality Snapshot: Below Average management risk is observed at GKB Ophthalmics, Tejnaksh Health., Vanta Bioscience, Dhanvantri Jeev., and the rest. Average management risk is found at Family Care, while Good management risk is noted at Galaxy Medicare. Growth is classified as Good at GKB Ophthalmics and Family Care, while Below Average growth is seen at Adeshwar Meditex, Tejnaksh Health., Vanta Bioscience, Dhanvantri Jeev., and the rest. Average capital structure is present at Adeshwar Meditex, while Good capital structure is noted at GKB Ophthalmics, Tejnaksh Health., and Dhanvantri Jeev., with Excellent capital structure at Family Care.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Dhanvantri Jeev. at 26.19%, while the lowest is Tejnaksh Health. at -25.80%. Adeshwar Meditex does not have a 1-year return available for comparison. Additionally, peers with negative six-month returns include Samsrita Labs, Family Care, and Transgene Biotek.

How big is Adeshwar Meditex?

As of 31st August, Adeshwar Meditex Ltd has a market capitalization of 25.00 Cr, classifying it as a Micro Cap, with no available financial data for net sales or net profit for the latest four quarters. The balance sheet as of March 2025 shows Shareholder's Funds of 36.96 Cr and Total Assets of 71.97 Cr.

As of 31st August, <BR><BR>Market Cap: Adeshwar Meditex Ltd has a market capitalization of 25.00 Cr, categorizing it as a Micro Cap.<BR><BR>Recent Quarterly Performance: There is no valid financial data available for net sales or net profit for the latest four quarters.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2025, with Shareholder's Funds amounting to 36.96 Cr and Total Assets valued at 71.97 Cr.

When is the next results date for Adeshwar Meditex Ltd?

The next results date for Adeshwar Meditex Ltd is 21 May 2026.

The next results date for Adeshwar Meditex Ltd is scheduled for 21 May 2026.

Is Adeshwar Meditex overvalued or undervalued?

As of November 13, 2025, Adeshwar Meditex is considered undervalued with a favorable outlook, featuring a PE ratio of 11.33 and an EV to EBITDA of 6.75, significantly lower than its peers, despite a year-to-date stock underperformance of -37.5% compared to the Sensex's 8.11%.

As of 13 November 2025, Adeshwar Meditex has moved from a fair to an attractive valuation grade, indicating a more favorable outlook for the company. The stock is currently considered undervalued, especially when compared to its peers. Key ratios include a PE ratio of 11.33, an EV to EBITDA of 6.75, and a Price to Book Value of 0.62, which suggest that the company is trading at a significant discount relative to its earnings and asset value.<BR><BR>In comparison to its peers, Adeshwar Meditex stands out with a much lower PE ratio than Poly Medicure, which has a PE of 55.2, and Blue Jet Health at 28.63. The EV to EBITDA ratio of 6.75 also highlights its attractiveness compared to other expensive peers like Laxmi Dental at 38.93. Despite the recent underperformance of Adeshwar Meditex's stock against the Sensex, with a YTD return of -37.5% compared to the Sensex's 8.11%, the current valuation metrics suggest that it presents a compelling investment opportunity.

How has been the historical performance of Adeshwar Meditex?

Adeshwar Meditex reported a net profit of 0.79 crore and net sales of 64.76 crore for the year ending March 2022, with an operating profit margin of 5.2%. Total liabilities and assets were both 72.45 crore, and the book value per share increased to 21.45.

Answer:<BR>The historical performance of Adeshwar Meditex shows a consolidated net profit of 0.79 crore for the year ending March 2022, with net sales recorded at 64.76 crore. The total operating income for the same period was also 64.76 crore, while total expenditure, excluding depreciation, amounted to 61.39 crore, resulting in an operating profit (PBDIT) of 3.60 crore. The profit before tax was 1.19 crore, leading to a profit after tax of 0.79 crore. The earnings per share (EPS) stood at 0.55, with a diluted EPS of 0.59. The operating profit margin was 5.2%, and the profit after tax margin was 1.22%. <BR><BR>In terms of balance sheet performance, the total liabilities as of March 2022 were 72.45 crore, with total assets also at 72.45 crore. The company's shareholder's funds were reported at 30.95 crore. Over the years, the book value per share has shown a steady increase, reaching 21.45 by March 2022. Cash flow from operating activities was negative at -2.00 crore for the year ending March 2022, while the net cash inflow/outflow was 0.00 crore. The company has maintained a consistent share capital of 14.43 crore since March 2021, indicating stability in its equity base.

Who are the top shareholders of the Adeshwar Meditex?

The top shareholders of Adeshwar Meditex include Abhinandan N with 29.83%, Ashalata B Raut at 6.11%, and individual investors collectively owning 36.96%. There are no mutual funds or foreign institutional investors holding shares in the company.

The top shareholders of Adeshwar Meditex include the promoters, with Abhinandan N holding the largest share at 29.83%. The highest public shareholder is Ashalata B Raut, who holds 6.11%. Additionally, individual investors collectively own 36.96% of the company's shares. There are currently no mutual funds or foreign institutional investors holding shares in the company.